Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced results from new post-hoc analyses of KRYSTEXXA (pegloticase) pivotal Phase III and open-label extension ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE